Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Top Page
Aldeyra Therapeutics
(NASDAQ:ALDX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▼(-15.73% Downside)
Action:UpgradedDate:04/02/26
The score is pressured primarily by weak financial performance (no revenue, ongoing losses, and elevated cash burn risk) and bearish technicals (sharp downtrend with negative momentum). Corporate events are mixed—debt repayment is a positive, but the second FDA rejection is a significant negative—and valuation support is limited given negative earnings and no dividend.
Positive Factors
Debt Repayment & Cash Runway
Paying off the $15M Hercules facility removes a near-term debt maturity and related covenants, lowering fixed financing costs and refinancing risk. Coupled with management's stated cash runway into 2028, this boosts medium-term financial flexibility and reduces pressure to raise immediate capital.
Negative Factors
No Revenue & Persistent Losses
As a clinical-stage company with no product sales, sustained operating losses erode equity and necessitate ongoing external funding. Until commercialization occurs, the firm remains dependent on capital markets, increasing dilution risk and constraining long-term investment flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Repayment & Cash Runway
Paying off the $15M Hercules facility removes a near-term debt maturity and related covenants, lowering fixed financing costs and refinancing risk. Coupled with management's stated cash runway into 2028, this boosts medium-term financial flexibility and reduces pressure to raise immediate capital.
Read all positive factors
Aldeyra Therapeutics (ALDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$95.69M
Dividend YieldN/A
Average Volume (3M)5.15M
Price to Earnings (P/E)―
Beta (1Y)2.58
Revenue GrowthN/A
EPS Growth4.23%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,182,780
10 Day Avg. Volume2,076,415
30 Day Avg. Volume5,148,737
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-412.99
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.50Price Target Upside208.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$51.15M
Aldeyra Therapeutics Business Overview & Revenue Model
Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is ...
How the Company Makes Money
Aldeyra is not known to have a commercialized product generating recurring product sales; as a clinical-stage biotech, it primarily funds operations through capital raising (e.g., public equity offerings) and other financing activities rather than...
Aldeyra Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -251.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -31.69M | -53.68M | -35.21M | -60.07M | -55.77M |
| Net Income | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
Balance Sheet | |||||
| Total Assets | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Cash, Cash Equivalents and Short-Term Investments | 70.04M | 101.15M | 142.82M | 174.30M | 229.79M |
| Total Debt | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M |
| Total Liabilities | 27.81M | 33.60M | 28.53M | 30.28M | 27.40M |
| Stockholders Equity | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
Cash Flow | |||||
| Free Cash Flow | -33.35T | -43.21M | -30.33M | -56.65M | -42.56M |
| Operating Cash Flow | -33.35T | -43.21M | -30.33M | -56.64M | -42.56M |
| Investing Cash Flow | 47.74T | -44.92M | 30.00M | -29.95M | -7.81K |
| Financing Cash Flow | 1.12T | -171.42K | -1.27M | 1.22M | 194.50M |
Aldeyra Therapeutics Technical Analysis
Negative
1.78
Price Trends
3.91
Negative
4.39
Negative
4.78
Negative
Market Momentum
-0.69
Negative
34.18
Neutral
42.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.95, below the 50-day MA of 3.91, and below the 200-day MA of 4.78, indicating a bearish trend. The MACD of -0.69 indicates Negative momentum. The RSI at 34.18 is Neutral, neither overbought nor oversold. The STOCH value of 42.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALDX.
Aldeyra Therapeutics Risk Analysis
Aldeyra Therapeutics disclosed 89 risk factors in its most recent earnings report. Aldeyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aldeyra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $827.24M | 3.16 | 1.71% | ― | ― | 12.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $353.78M | -7.84 | -51.44% | ― | ― | 68.53% | |
45 Neutral | $269.43M | -4.58 | 105.48% | ― | -3.91% | 37.89% | |
44 Neutral | $371.36M | -1.23 | -113.81% | ― | ― | 20.71% | |
43 Neutral | $151.40M | -8.62 | 25.65% | ― | ― | 18.82% | |
41 Neutral | $95.69M | ― | -63.75% | ― | ― | 4.23% |
* Healthcare Sector Average
ALDX
Aldeyra Therapeutics
1.78
-0.34
-16.04%
OMER
Omeros
11.49
4.50
64.38%
GALT
Galectin Therapeutics
2.30
0.96
71.64%
FHTX
Foghorn Therapeutics
4.59
1.00
27.86%
CADL
Candel Therapeutics
4.83
-0.34
-6.58%
NMRA
Neumora Therapeutics, Inc.
2.04
1.37
204.48%
Aldeyra Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
Positive
Apr 1, 2026
Aldeyra Therapeutics, Inc. previously entered into a Loan and Security Agreement in March 2019 with Hercules Capital, Inc. and a syndicate of lenders, known as the Hercules Credit Facility, which had a scheduled maturity date of April 1, 2026. On ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Issues Second Complete Response Letter for Reproxalap
Negative
Mar 17, 2026
On March 17, 2026, Aldeyra Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter rejecting the New Drug Application for reproxalap in dry eye disease, citing a lack of substantial evidence of efficacy,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.